CUPID 2011

1 Treatments

**Studied treatment**  SERCA2a gene therapy  
MYDICAR®, SERCA2a (sarcoplasmic reticulum Ca2+-ATPase) gene administered using an adeno-associated viral vector in a single intracoronary dose

**Control treatment**  placebo

**Concomittant treatments**  -

**cell type**  -

**Cell injection procedure**  -

2 Patients

**Patients**  patients NYHA class 3-4 heart failure and an LVEF <35%

**Inclusion criteria**  -

**Exclusion criteria**  -

3 Methods

**Blinding**  double-blind

**Design**  Parallel groups

**Centers**  16

**Geographical area**  US

**Sizes**  25/14

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>acute heart failure</td>
<td>-/25</td>
<td>-/14</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>ventricular tachycardia</td>
<td>-/25</td>
<td>-/14</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>NYHA deterioration</td>
<td>-/25</td>
<td>-/14</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiac event</td>
<td>-/25</td>
<td>-/14</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all-cause mortality</td>
<td>-/25</td>
<td>-/14</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References
